Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner…

What Is Arm? What to Know About the Circuit Designer

What to Read Next

Big Pharma’s Battle With the Biden Administration Could Have Legs

Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the…

Biden FTC’s Antitrust Bark Proves Worse Than Its Bite

The FTC settlement with Amgen will pave the way for more healthcare deal making.

J&J’s $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion 

The healthcare giant’s separation of its consumer-health business arms it with billions in cash for allocating…

Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle

The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8…

To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit-Card Debts

Some people are paying more than $10,000 a year for Ozempic and Mounjaro.

Opinion | Drug Price Controls Mean Slower Cures

The squeeze on pharma begins, and the effects won’t be what President Biden claims.

Cancer Runs in Families. Too Few Are Getting Tested.

Doctors are recommending genetic tests to more cancer patients and their families. Costs have dropped, and…